Biotech Leader Jeremy Levin Warns of Challenges Facing American Industry
STAT+: Biotech veteran Jeremey Levin on why the industry’s future is secure, but American leadership is at risk

Image: Stat
Jeremy Levin, a prominent figure in biotech, warns that while scientific advancements continue, American leadership in the industry is jeopardized by political instability and weakening institutions. His new book discusses the need for federal changes to support biotech investment and address regulatory challenges.
- 01Jeremy Levin is the founder and chairman of Ovid Therapeutics and former CEO of Teva Pharmaceuticals.
- 02In his book, Levin highlights that political upheaval and weakening institutions threaten the biotech industry's future.
- 03He calls for federal changes to incentivize investment in biotech and urges pharmaceutical companies to address regulatory challenges.
- 04Levin emphasizes the importance of public trust in science and the need for the industry to advocate for itself during times of institutional instability.
- 05The biotech industry is experiencing rapid scientific advancements despite the surrounding challenges.
Advertisement
In-Article Ad
In a recent discussion, Jeremy Levin, a veteran in the biotech sector and founder of Ovid Therapeutics, expressed concerns about the future of the American biotech industry. While acknowledging the remarkable scientific breakthroughs being achieved, Levin cautioned that the foundational institutions supporting these advancements are under strain. He attributes this instability to factors such as political upheaval, diminishing public trust, and a shift towards short-term investment strategies. In his new book, “Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust,” Levin argues that these issues pose significant risks to the industry's leadership in the U.S. He advocates for federal reforms that would encourage investment in biotech and urges pharmaceutical companies to vocalize the detrimental effects of regulatory challenges. Levin stresses the critical need for the industry to unite and advocate for itself amidst these turbulent times, as silence from industry leaders could exacerbate the challenges faced by the sector. His insights were shared during an episode of “The Readout Loud,” where he discussed the pressing need for action to secure the future of biotechnology in America.
Advertisement
In-Article Ad
The biotech industry is crucial for economic growth and healthcare advancements in the U.S., and its stability affects public health and job creation.
Advertisement
In-Article Ad
Reader Poll
What do you think is the biggest challenge facing the biotech industry today?
Connecting to poll...
Read the original article
Visit the source for the complete story.




